Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Researchers are evaluating the Freenome Multiomics Blood Test as a new way to screen for lung cancer in people at high risk. This observational study includes adults aged 50 and older who are current or former smokers with a significant smoking history. The goal is to see how well this blood test works alongside the standard Low-Dose Computed Tomography LDCT screening to detect lung cancer early. Participants will provide a blood sample of 50 ml that will be tested and stored by Freenome or its designee. They will also undergo a standard LDCT chest scan, ideally on the same day as the blood draw or within 45 days afterward. The study collects additional information such as medical history, lifestyle, environmental exposures, and results from diagnostic tests related to lung cancer detection. Participants will be monitored for at least 24 months following their baseline chest CT scan to track health outcomes. Researchers will review clinical data, imaging reports, and lab results during this period. The main outcome measured is the blood tests sensitivity and specificity in detecting lung cancer at 12 months, with additional measurements at 24 months. The study may end early if participants withdraw or pass away.
Actively Recruiting
Healthy Volunteer
This research aims to improve colorectal cancer screening by identifying and addressing barriers in community health centers CHCs with diverse populations. The study focuses on people aged 45 and older, examining baseline screening needs and disparities. Researchers will analyze electronic health records and use focus groups with CHC staff to understand screening challenges and perceptions about screening age changes and strategies. The study also seeks to develop and test ways to improve screening at patient, provider, and system levels using rapid cycle testing. The study involves several steps first, analyzing data from health records and population management platforms to understand screening patterns and resource needs. Second, conducting focus groups with various CHC staff to identify barriers and attitudes toward screening and new strategies like using technology and medical assistant involvement. Third, developing implementation strategies based on these findings and testing them individually at each CHC using a design where each center acts as its own control. Strategies may include patient text messages, staff training, and workflow changes. Participants, who are CHC staff involved in colorectal cancer screening, will engage in focus groups and implementation testing lasting about four months. Researchers will collect data on how acceptable, feasible, and appropriate the strategies are through surveys and observation. They will also measure changes in screening rates. The study uses detailed data management and analysis methods to track progress and outcomes, aiming to tailor and optimize screening interventions in these health centers.